Known targets — ChEMBL curated mechanism
DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA
The experimentally established mechanism targets of Tromethamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tromethamine SCHEMBL8530527 | 1.00 | MEN1 (0.59) | MEN1LMNAKMT2AS1PR1 | |
| Tromethamine SCHEMBL466420 | 0.97 | MEN1 (0.62) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL2898170 | 0.85 | MEN1 (0.48) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL2862081 | 0.81 | MEN1 (0.67) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL9644059 | 0.81 | MEN1 (0.77) | MEN1LMNAKMT2AS1PR1 | |
| Tromethamine SCHEMBL445853 | 0.80 | MEN1 (0.91) | MEN1LMNAKMT2AS1PR1 | |
| Tromethamine SCHEMBL1270294 | 0.80 | MEN1 (0.91) | MEN1LMNAKMT2AS1PR1 | |
| Tromethamine SCHEMBL2188 | 0.80 | — | — | |
| Tromethamine SCHEMBL2313359 | 0.80 | MEN1 (0.91) | MEN1LMNAKMT2AS1PR1 | |
| Tromethamine SCHEMBL1524832 | 0.80 | MEN1 (0.91) | MEN1LMNAKMT2AS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100357267-C | Use of 2, 4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors | NOVARTIS AG (CH) | 2007-12-26 | — | — | CN | disclosed |
| CN-1351587-A | Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors | NOVARTIS AG (CH) | 2002-05-29 | — | — | CN | disclosed |
| WO-1998015541-A1 | NOVEL ISOXAZOL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND A PROCESS FOR THE PREPARATION OF THE NOVEL COMPOUNDS | EGIS Gyógyszergyár Rt. (HU) | 1998-04-16 | — | — | WO | disclosed |
| EP-0449812-B1 | METHOD OF PRE-TREATING SAMPLES IN PEROXIDASE-CATALYZED ENZYME ASSAYS | SANOFI DIAGNOSTICS PASTEUR INC (US) | 1995-09-13 | — | — | EP | disclosed |
| WO-1995005376-A1 | SUBSTITUTED 2(5H)FURANONE, 2(5H)THIOPHENONE AND 2(5H)PYRROLONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1995-02-23 | — | — | WO | disclosed |
| WO-1993021219-A1 | ENDOTHELIN ANTAGONISTS II | WARNER-LAMBERT COMPANY (US) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993008122-A1 | CONTRAST AGENTS AND COMPOSITIONS FOR RADIOLOGICAL IMAGING, AND RADIOLOGICAL IMAGING METHOD UTILIZING SAME | GUERBET S.A. (FR) | 1993-04-29 | — | — | WO | disclosed |
| EP-0449812-A4 | METHOD OF PRE-TREATING SAMPLES IN PEROXIDASE-CATALYZED ENZYME ASSAYS | — | 1991-10-30 | — | — | EP | disclosed |
| EP-0449812-A1 | METHOD OF PRE-TREATING SAMPLES IN PEROXIDASE-CATALYZED ENZYME ASSAYS. | KALLESTAD DIAGNOSTICS INC (US) | 1991-10-09 | — | — | EP | disclosed |
| WO-1990007115-A1 | METHOD OF PRE-TREATING SAMPLES IN PEROXIDASE-CATALYZED ENZYME ASSAYS | KALLESTAD DIAGNOSTICS, INC. (US) | 1990-06-28 | — | — | WO | disclosed |